Dajani O, Philips I, Størkson EK, Balstad TR, Brown LR, Bye A, Dolan R, Greil C, Hjermstad M, Jakobsen G, Kaasa S, McDonald J, Ottestad I, Sayers J, Simpson M, Sousa MS, Vagnildhaug OM, Yule MS, Laird BJA, Skipworth RJE, Solheim TS, Stares M, Arends J, Cancer Cachexia Endpoints Working Group(2025) Oncological and Survival Endpoints in Cancer Cachexia Clinical Trials: Systematic Review 6 of the Cachexia Endpoints Series J Cachexia Sarcopenia Muscle, 16(2), e13756 DOI 10.1002/jcsm.13756, PubMed 40065459
Fosså A, Molin D, Bröckelmann PJ, Schneider G, Schnetzke U, Linderoth J, Kamper PMH, Leppä SM, Meissner J, Schaub V, Lia K, Fuchs M, Borchmann P, Böll B(2025) Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG-NLG phase II BVB trial Hemasphere, 9(3), e70099 DOI 10.1002/hem3.70099, PubMed 40124718
Tanoli Z, Fernández-Torras A, Özcan UO, Kushnir A, Nader KM, Gadiya Y, Fiorenza L, Ianevski A, Vähä-Koskela M, Miihkinen M, Seemab U, Leinonen H, Seashore-Ludlow B, Tampere M, Kalman A, Ballante F, Benfenati E, Saunders G, Potdar S, Gómez García I, García-Serna R, Talarico C, Beccari AR, Schaal W, Polo Aet al.(2025) Computational drug repurposing: approaches, evaluation of in silico resources and case studies Nat Rev Drug Discov(in press) DOI 10.1038/s41573-025-01164-x, PubMed 40102635
